Loading stock data…
$3.46-0.11 (-3.08%)
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
Ironwood Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.46 with a market capitalization of $674M. Wall Street consensus targets $6.10 (4 analysts), implying a +76.3% move over the next 12 months. The stock is currently 40% below its 52-week high of $5.78, remaining 13.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $113.04M↑ | $106.51M↑ | $47.71M↓ | $122.06M↑ | $85.24M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $79.31M↑ | $72.53M↑ | $6.55M↓ | $77.68M↑ | $45.07M |
| Net Income | $51.29M↑ | $40.77M↑ | -$2.28M↓ | $40.08M↑ | $23.60M |
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase typ...